Beta

Oculis holding agOCS.US Overview

US StockHealthcare
(No presentation for OCS)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

OCS AI Insights

OCS Overall Performance

OCS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

OCS Recent Performance

-1.47%

Oculis holding ag

-1.10%

Avg of Sector

-0.49%

S&P500

OCS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check OCS's Trend

OCS Key Information

OCS Valuation Metrics

OCS Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

Price of OCS

OCS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

OCS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.73
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1278.66
PB Ratio
6.13
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-6668.26%
Revenue Growth (YoY)
116.33%
Profit Growth (YoY)
116.33%
3-Year Revenue Growth
71.07%
3-Year Profit Growth
136.12%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.73
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1278.66
PB Ratio
6.13
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-6668.26%
Revenue Growth (YoY)
116.33%
Profit Growth (YoY)
116.33%
3-Year Revenue Growth
71.07%
3-Year Profit Growth
136.12%
  • When is OCS's latest earnings report released?

    The most recent financial report for Oculis holding ag (OCS) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating OCS's short-term business performance and financial health. For the latest updates on OCS's earnings releases, visit this page regularly.

  • What is the operating profit of OCS?

    According to the latest financial report, Oculis holding ag (OCS) reported an Operating Profit of -19.85M with an Operating Margin of -1,655.13% this period, representing a decline of 14.98% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is OCS's revenue growth?

    In the latest financial report, Oculis holding ag (OCS) announced revenue of 1.2M, with a Year-Over-Year growth rate of 39,866.67%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does OCS have?

    As of the end of the reporting period, Oculis holding ag (OCS) had total debt of 2.31M, with a debt ratio of 0.01. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does OCS have?

    At the end of the period, Oculis holding ag (OCS) held Total Cash and Cash Equivalents of 81.33M, accounting for 0.34 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does OCS go with three margins increasing?

    In the latest report, Oculis holding ag (OCS) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -1,655.13%%, and net margin of -1,961.1%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess OCS's profit trajectory and future growth potential.

  • Is OCS's EPS continuing to grow?

    According to the past four quarterly reports, Oculis holding ag (OCS)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.41. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of OCS?

    Oculis holding ag (OCS)'s Free Cash Flow (FCF) for the period is -16.72M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 60.53% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of OCS?

    The latest valuation data shows Oculis holding ag (OCS) has a Price-To-Earnings (PE) ratio of -12.67 and a Price/Earnings-To-Growth (PEG) ratio of -0.3. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.